# Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients

> **NCT01345916** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 932 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CHF 1535 100/6 NEXT DPI® 2 months
- **DRUG:** CHF 1535 100/6 pMDI 2 months
- **DRUG:** BDP DPI 2 months

## Key facts

- **NCT ID:** NCT01345916
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 932 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345916, "Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01345916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*